{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kravchenko OV"],"funding":["National Institute for Aging","NCATS","National Heart, Lung and Blood Institute","NCATS N3C Data Enclave","National COVID Cohort Collaborative","AHRQ","Pharmacoepidemiology T32 Training Program","NLM"],"pagination":["e066846"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9806069"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["<h4>Objective</h4>The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE.<h4>Design</h4>We used nested case-control study design.<h4>Setting</h4>This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repositor"],"journal":["BMJ open"],"pubmed_title":["Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C)."],"pmcid":["PMC9806069"],"funding_grant_id":["5T15LM007059-34","N/A","T32HL139426","U24 TR002306","R01 HS025984","1K01AG070329"],"pubmed_authors":["Leonard CE","Kocis PT","Villa Zapata L","Tan M","Gomez-Lumbreras A","Boyce RD","N3C consortium","Kravchenko OV","Mehta H","Andersen KM","Alexander GC","Malone DC"],"additional_accession":[]},"is_claimable":false,"name":"Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).","description":"<h4>Objective</h4>The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE.<h4>Design</h4>We used nested case-control study design.<h4>Setting</h4>This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repositor","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-19T04:42:50.796Z","creation":"2025-04-19T04:42:50.796Z"},"accession":"S-EPMC9806069","cross_references":{"pubmed":["36581417"],"doi":["10.1136/bmjopen-2022-066846"]}}